

**Cocoa Beach, Florida:** Ward Photonics has announced today the opening of enrollment in a clinical study for photobiomodulation for Lung Inflammation in patients recovering from pulmonary inflammation. This study will evaluate the use of red light to relieve inflammation and resulting respiratory distress in patients with ongoing symptoms after infection with COVID-19.

UltraSlim® by Ward Photonics will be used to painlessly and non-invasively treat pulmonary inflammation using the process of photobiomodulation. Photobiomodulation has been used for decades to treat pain and inflammation for a variety of maladies; Researchers have tested this type of treatment for inflammation of the lungs in animals with success; we believe this is the first study to evaluate its effects on human patients.

This study will use photobiomodulation to treat lingering symptoms from recent COVID infection by using red light to relieve inflammation of the lungs, improve breathing and increase oxygen saturation in the blood.

We believe that there is an ongoing need for minimally invasive treatments that do not interfere with first-line treatments for the COVID-19 infection.

UltraSlim® is FDA-cleared for three indications including: fat reduction, skin blemishes, and reduction of pain and inflammation. The FDA category for this type of light is called “Low-Level Laser Therapy” (LLLT) even though the light in this particular device is not a laser light.

The primary measures of the effectiveness of treatment for this study will be blood testing for D-dimer, IL-6, and C-reactive protein (CRP) as indicators of inflammation, as well as O<sub>2</sub> saturation after short physical stress as a measure of pulmonary function.

A secondary measure of the effectiveness of treatment for this study is a subjective evaluation of the patient’s overall well-being. Subjects will self-evaluate factors regarding their health, energy, and ability to breathe freely evaluated over the course of treatment, and measuring changes in well-being (if any).

Ideal candidates for this study include adults suffering from lingering respiratory distress from pulmonary inflammation, and who do not have a photo-sensitive condition or medication.

There will be no compensation for participation; however, treatment is provided at no cost to the patient.

Potential candidates apply online at: <https://www.oursmartfuture.com/telehealth/inova-pre-screening>

**About Ward Photonics:** Ward Photonics was established in 2013 by Terry J. Ward, M.H.A. in Cocoa Beach, Florida. Ward Photonics manufactures their devices at their headquarters, and is the leader in Low-Level Laser Therapy devices and photobiomodulation.

**Forward-Looking Statements:** Information contained herein contains ‘forward-looking statements’ within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended.” Sections 27A and 21E, both created by the Private Securities Litigation Reform Act of 1995 (PSLRA), provide certain statutory protections for qualifying companies in qualifying materials, for forward-looking statements. Although forward-looking statements contained in this announcement are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

**Contacts:**

Sponsor

Judson Ward

+1 800 392 5950, Ext. 5

[clinicaltrials@wardphotonics.com](mailto:clinicaltrials@wardphotonics.com)

Principal Investigator

Dr. Randal Horsley

(302) 934-7350

[drrlhorsley@gmail.com](mailto:drrlhorsley@gmail.com)

